$3.62 Billion is the total value of BB BIOTECH AG's 30 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Incyte Corp. | $308,181,000 | -12.0% | 3,698,322 | 0.0% | 8.52% | -13.7% | |
| VRTX | Vertex Pharmaceuticals Inc. | $240,468,000 | +8.8% | 1,475,445 | 0.0% | 6.65% | +6.7% | |
| HALO | Halozyme Therapeutics Inc. | $166,909,000 | -3.3% | 8,520,137 | 0.0% | 4.61% | -5.1% | |
| MYOV | Myovant Sciences Ltd. | $74,613,000 | +68.3% | 3,507,882 | 0.0% | 2.06% | +65.1% | |
| MGNX | MacroGenics Inc. | $65,426,000 | +32.4% | 2,600,412 | 0.0% | 1.81% | +30.0% | |
| AVXS | AveXis, Inc. | $49,778,000 | +11.7% | 402,800 | 0.0% | 1.38% | +9.6% | |
| ITCI | Intra-Cellular Therapies Inc. | $46,310,000 | +45.4% | 2,200,000 | 0.0% | 1.28% | +42.7% | |
| ALDR | Alder Biopharmaceuticals Inc. | $28,778,000 | +10.9% | 2,266,008 | 0.0% | 0.80% | +8.8% | |
| NVAX | Novavax Inc. | $17,493,000 | +69.4% | 8,330,000 | 0.0% | 0.48% | +66.0% | |
| CDTX | Cidara Therapeutics Inc. | $9,181,000 | -41.2% | 2,295,272 | 0.0% | 0.25% | -42.3% | |
| ACHN | Achillion Pharmaceuticals Inc. | $4,746,000 | +28.8% | 1,279,340 | 0.0% | 0.13% | +26.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N V #1
- Biotech Invest N V #2
- Biotech Target N V #3
- Biotech Growth N V #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-15 |
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.